Author: Kevin Grogan

Fresh from announcing a major licensing deal with Isis Pharmaceuticals, Genzyme Corp has taken the opportunity of the JPMorgan investor conference in San Francisco to give details of its strong sales growth in 2007.

People taking statins may be less likely to develop cancer,according to a new study published in the Journal of the National Cancer Institute.

Genzyme Corp is forking out $325 million in upfront fees and could pay over $1.5 billion more as part of a licensing deal for Isis Pharmaceuticals’ new lipid-lowerer mipomersen.

Takeda Pharmaceutical Co has filed its new diabetes treatment alogliptin with US regulators in a bid to reduce its reliance on Actos and start making up ground on Merck & Co’s dipeptidyl peptidase-4 inhibitor Januvia.

GlaxoSmithKline and AstraZeneca have been quick to respond to the latest move by the UK’s Serious Fraud Office to step up its investigation into alleged bribes connected with the oil-for-food programme in Iraq during the Saddam Hussein regime.